Coenzyme Q10 for heart failure

Saadi, Tareq Al; Assaf, Yazan; Farwati, Medhat; Turkmani, Khaled; Al‐Mouakeh, Ahmad; Shebli, Baraa; Khoja, Mohammed; Essali, Adib; Madmani, Mohammed Eid

doi:10.1002/14651858.cd008684.pub3

Cited by 30 publications

(25 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Al Saadi et al included 11 studies to review the efficacy of coenzyme Q10 in heart failure, and concluded that the included studies provide moderate-quality evidence for the benefit of coenzyme Q10 in reducing all-cause mortality and hospitalization related to heart failure. However, there was low-quality evidence to conclude whether coenzyme Q10 improves either left ventricular ejection or exercise capacity ( 127 ). Large-scale and high quality clinical trials are needed to further evaluate the efficacy of coenzyme Q10.…”

Section: Targeting Mitochondrial Dysfunction As a Therapeutic Strategymentioning

confidence: 99%

Mitochondrial dysfunction in heart failure and its therapeutic implications

Liu

Pan

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The ATP consumption in heart is very intensive to support muscle contraction and relaxation. Mitochondrion is the power plant of the cell. Mitochondrial dysfunction has long been believed as the primary mechanism responsible for the inability of energy generation and utilization in heart failure. In addition, emerging evidence has demonstrated that mitochondrial dysfunction also contributes to calcium dysregulation, oxidative stress, proteotoxic insults and cardiomyocyte death. These elements interact with each other to form a vicious circle in failing heart. The role of mitochondrial dysfunction in the pathogenesis of heart failure has attracted increasing attention. The complex signaling of mitochondrial quality control provides multiple targets for maintaining mitochondrial function. Design of therapeutic strategies targeting mitochondrial dysfunction holds promise for the prevention and treatment of heart failure.

show abstract

Section: Targeting Mitochondrial Dysfunction As a Therapeutic Strategymentioning

confidence: 99%

Mitochondrial dysfunction in heart failure and its therapeutic implications

Liu

Pan

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis of 8 clinical trials with 327 patients undergoing cardiac surgery with cardiopulmonary bypass, CoQ 10 (30-600 mg/day) for 12 h to 14 days before surgery significantly reduced inotropic drugs requirement and incidence of ventricular arrhythmias after surgery, with no significant effect in terms of cardiac index, the incidence of atrial fibrillation, or duration of hospital stay (69). In a recent Cochrane review that included 11 RCTs with 1,573 patients with HF, CoQ 10 reduced all-cause mortality (risk ratio [RR]: 0.58; 95% CI: 0.35-0.95) and HF-related hospitalization (RR: 0.62; 95% CI: 0.49-0.78) compared with the control group (70). A significant improvement in LVEF was also observed with CoQ 10 supplementation in comparison with the control group (MD: 1.77; 95% CI: 0.09-3.44) (70).…”

Section: Related Evidence From Clinical Studies and Future Prospectivementioning

confidence: 99%

“…In a recent Cochrane review that included 11 RCTs with 1,573 patients with HF, CoQ 10 reduced all-cause mortality (risk ratio [RR]: 0.58; 95% CI: 0.35-0.95) and HF-related hospitalization (RR: 0.62; 95% CI: 0.49-0.78) compared with the control group (70). A significant improvement in LVEF was also observed with CoQ 10 supplementation in comparison with the control group (MD: 1.77; 95% CI: 0.09-3.44) (70). In a cohort of 443 Swedish healthy elderly individuals, CoQ 10 (200 mg/day) combined with selenium (200 µg/day) for 4 years resulted in reduced CV death compared with placebo (5.9 vs. 12.6%; p = 0.015), a favorable effect that persisted for 10 years after the intervention (HR: 0.51; 95% CI: 0.36-0.74, p = 0.0003) (71,72).…”

Section: Related Evidence From Clinical Studies and Future Prospectivementioning

confidence: 99%

Coenzyme Q10 Reduces Infarct Size in Animal Models of Myocardial Ischemia-Reperfusion Injury: A Meta-Analysis and Summary of Underlying Mechanisms

Awad

Sayed

Banach

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectiveEffective interventions that might limit myocardial ischemia-reperfusion (I/R) injury are still lacking. Coenzyme Q10 (CoQ10) may exert cardioprotective actions that reduce myocardial I/R injury. We conducted this meta-analysis to assess the potential cardioprotective effect of CoQ10 in animal models of myocardial I/R injury.MethodsWe searched PubMed and Embase databases from inception to February 2022 to identify animal studies that compared the effect of CoQ10 with vehicle treatment or no treatment on myocardial infarct size in models of myocardial I/R injury. Means and standard deviations of the infarct size measurements were pooled as the weighted mean difference with 95% confidence interval (CI) using the random-effects model. Subgroup analyses were also conducted according to animals' species, models' type, and reperfusion time.ResultsSix animal studies (4 in vivo and 2 ex vivo) with 116 animals were included. Pooled analysis suggested that CoQ10 significantly reduced myocardial infarct size by −11.36% (95% CI: −16.82, −5.90, p < 0.0001, I2 = 94%) compared with the control group. The significance of the pooled effect estimate was maintained in rats, Hartley guinea pigs, and Yorkshire pigs. However, it became insignificant in the subgroup of rabbits −5.29% (95% CI: −27.83, 17.26; I2 = 87%). Furthermore, CoQ10 significantly reduced the myocardial infarct size regardless of model type (either in vivo or ex vivo) and reperfusion time (either ≤ 4 h or >4 h).ConclusionCoenzyme Q10 significantly decreased myocardial infarct size by 11.36% compared with the control group in animal models of myocardial I/R injury. This beneficial action was retained regardless of model type and reperfusion time.

show abstract

“…Despite the lack of consistency in individual trial results, the authors suggested that “based on the current evidence and excellent safety profile of coenzyme Q10, there is a case for the use of coenzyme Q10 as an adjunctive therapy in HF, particularly for those patients unable to tolerate mainstream medical therapies” [ 72 ]. A Cochrane review including 11 studies with 1573 participants, comparing coenzyme Q10 to placebo or conventional therapy (control) showed that coenzyme Q10 may reduce all-cause mortality and hospitalization for HF [ 73 ].…”

Section: Coenzyme Q10 Supplementation In Hf—evidence From Clinical St...mentioning

confidence: 99%

Heart Failure—Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10

Filipiak‬

Surma

Romańczyk

2022

JCDD

View full text Add to dashboard Cite

Heart failure (HF) is a global epidemic that contributes to the deterioration of quality of life and its shortening in 1–3% of adult people in the world. Pharmacotherapy of HF should rely on highly effective drugs that improve prognosis and prolong life. Currently, the ESC guidelines from 2021 indicate that ACEI, ARNI, BB, and SGLT2 inhibitors are the first-line drugs in HF. It is also worth remembering that the use of coenzyme Q10 brought many benefits in patients with HF. Coenzyme Q10 is a very important compound that performs many functions in the human body. The most important function of coenzyme Q10 is participation in the production of energy in the mitochondria, which determines the proper functioning of all cells, tissues, and organs. The highest concentration of coenzyme Q10 is found in the tissue of the heart muscle. As the body ages, the concentration of coenzyme Q10 in the tissue of the heart muscle decreases, which makes it more susceptible to damage by free radicals. It has been shown that in patients with HF, the aggravation of disease symptoms is inversely related to the concentration of coenzyme Q10. Importantly, the concentration of coenzyme Q10 in patients with HF was an important predictor of the risk of death. Long-term coenzyme Q10 supplementation at a dose of 300 mg/day (Q-SYMBIO study) has been shown to significantly improve heart function and prognosis in patients with HF. This article summarizes the latest and most important data on CoQ10 in pathogenesis.

show abstract

Coenzyme Q10 for heart failure

Cited by 30 publications

References 91 publications

Mitochondrial dysfunction in heart failure and its therapeutic implications

Mitochondrial dysfunction in heart failure and its therapeutic implications

Coenzyme Q10 Reduces Infarct Size in Animal Models of Myocardial Ischemia-Reperfusion Injury: A Meta-Analysis and Summary of Underlying Mechanisms

Heart Failure—Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10

Contact Info

Product

Resources

About